Litigation Details for ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited (D. Del. 2020)

ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited (D. Del. 2020)

Docket		Date Filed	2020-07-24
Court	District Court, D. Delaware	Date Terminated	2024-05-07
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To
Parties	TEVA PHARMACEUTICALS USA, INC.
Patents	10,028,944; 10,188,632; 10,449,185; 10,517,860; 6,756,393; 6,815,458; 7,115,634; 7,601,740; 7,659,285; 7,732,615; 7,741,356; 7,786,158; 7,863,296; 7,923,564; 8,344,011; 8,618,130; 8,691,860; 8,921,393; 9,115,091; 9,296,694; 9,364,489; 9,566,271; 9,675,587; 9,789,125
Attorneys	David A. Bilson
Firms	Saul Ewing Arnstein & Lehr LLP
Link to Docket	External link to docket

Details for ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2020-07-24	1	Complaint	States Patent Nos. 7,601,740 (“the ’740 patent”), 7,732,615 (“the ’615 patent”), 10,449,185 (“the ’185…’185 patent”), and 10,646,480 (“the ’480 patent”) (collectively “the patents-in-suit”). This action arises… of the ’740 patent is attached as Exhibit A. 26. ACADIA owns the ’740 patent. 27.…of the ’615 patent is attached as Exhibit B. 28. ACADIA owns the ’615 patent. 29.… of the ’185 patent is attached as Exhibit C. 30. ACADIA owns the ’185 patent.	External link to document
2021-08-10	117	Stipulation-General (See Motion List for Stipulation to Extend Time)	16 of U.S. Patent No. 10,646,480, Claim 3 of U.S. Patent No. 10,449,185, and Claims…8 of U.S. Patent No. 10,646,480 and Claim 1 of U.S. Patent No. 10,449,185; and … of the ’480 patent, the ’185 patent, and the ’891 patent with respect to … lubricant” appearing in Claims 1 and 6 of U.S. Patent No. 10,849,891; • “a D90 particle…Claims 7 and 11 of U.S. Patent No. 10,849,891; 38842524.2 Case 1:20-cv-00985-RGA Document	External link to document
2020-09-01	12	Patent/Trademark Report to Commissioner of Patents	,923,564 ;8,618,130 ;8,921,393 ;9,566,271 ;10,028,944 . (Dorsney, Kenneth) (Entered: 09/01/2020) 1… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,659,285 ;7,923,564…July 2020 7 May 2024 1:20-cv-00985 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2021-08-27	122	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,601,740 ;7,732,615 ;10,449,185 ;10,517,860…July 2020 7 May 2024 1:20-cv-00985 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2021-09-10	125	Claim Construction Chart	United States Patent Nos. 10,449,185 (“the ’185 patent”); 10,646,480 (“the ’480 patent”); and 10,849,…U.S. Patent No. 10,449,185 B U.S. Patent No. 10,646,480 C U.S. Patent No. …for certain terms of the ’185 patent, the ’480 patent, and the ’891 patent. In addition to their proposed… Copies of the ’185 patent, the ’480 patent, and the ’891 patent, and portions of the intrinsic…construction ’480 patent specification: pimavanserin tartrate ’480 patent specification:	External link to document
2022-01-28	137	Joint Claim Construction Brief	construction: U.S. Patent No. 10,449,185 (“the ’185 patent”); the ’480 patent; and U.S. Patent No. 10,849,891…” (’185 patent, claim 1; ’480 patent, claims 1, 5, 12, 14, 15; ’891 patent, claim 1…” (’185 patent, claim 1; ’480 patent, claims 1, 5, 12, 14, 15; ’891 patent, claim 1…,891 (“the ’891 patent”) (“the asserted formulation patents”). These patents are … (’185 patent, claim 1; ’480 patent, claims 1, 5, 12, 14; ’891 patent, claim 1)	External link to document